203 related articles for article (PubMed ID: 30694363)
1. Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey.
Yu J; Paranagama D; Geyer HL; Parasuraman S; Mesa R
Ann Hematol; 2019 May; 98(5):1119-1125. PubMed ID: 30694363
[TBL] [Abstract][Full Text] [Related]
2. Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey.
Yu J; Parasuraman S; Paranagama D; Bai A; Naim A; Dubinski D; Mesa R
BMC Cancer; 2018 Apr; 18(1):420. PubMed ID: 29653557
[TBL] [Abstract][Full Text] [Related]
3. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey.
Harrison CN; Koschmieder S; Foltz L; Guglielmelli P; Flindt T; Koehler M; Mathias J; Komatsu N; Boothroyd RN; Spierer A; Perez Ronco J; Taylor-Stokes G; Waller J; Mesa RA
Ann Hematol; 2017 Oct; 96(10):1653-1665. PubMed ID: 28780729
[TBL] [Abstract][Full Text] [Related]
4. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
Mesa R; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Boyle J; Mascarenhas JO
BMC Cancer; 2016 Feb; 16():167. PubMed ID: 26922064
[TBL] [Abstract][Full Text] [Related]
5. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.
Geyer HL; Andreasson B; Kosiorek HE; Dueck AC; Scherber RM; Martin KA; Butler KA; Harrison CN; Radia DH; Cervantes F; Kiladjian JJ; Reiter A; Birgegard G; Passamonti F; Senyak Z; Vannucchi AM; Paoli C; Xiao Z; Samuelsson J; Mesa RA
Cancer; 2016 Jun; 122(12):1888-96. PubMed ID: 27070130
[TBL] [Abstract][Full Text] [Related]
6. Approach to MPN Symptom Assessment.
Geyer H; Mesa RA
Curr Hematol Malig Rep; 2017 Oct; 12(5):381-388. PubMed ID: 28942516
[TBL] [Abstract][Full Text] [Related]
7. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.
Emanuel RM; Dueck AC; Geyer HL; Kiladjian JJ; Slot S; Zweegman S; te Boekhorst PA; Commandeur S; Schouten HC; Sackmann F; Kerguelen Fuentes A; Hernández-Maraver D; Pahl HL; Griesshammer M; Stegelmann F; Doehner K; Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Harrison CN; Radia D; Muxi P; Maldonado N; Besses C; Cervantes F; Johansson PL; Barbui T; Barosi G; Vannucchi AM; Passamonti F; Andreasson B; Ferrari ML; Rambaldi A; Samuelsson J; Birgegard G; Tefferi A; Mesa RA
J Clin Oncol; 2012 Nov; 30(33):4098-103. PubMed ID: 23071245
[TBL] [Abstract][Full Text] [Related]
8. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
Mesa RA; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Naim A; Parasuraman S; Boyle J; Mascarenhas JO
Cancer; 2017 Feb; 123(3):449-458. PubMed ID: 27690182
[TBL] [Abstract][Full Text] [Related]
9. The Myeloproliferative Neoplasm Landscape: A Patient's Eye View.
Petruk C; Mathias J
Adv Ther; 2020 May; 37(5):2050-2070. PubMed ID: 32329011
[TBL] [Abstract][Full Text] [Related]
10. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.
Geyer HL; Kosiorek H; Dueck AC; Scherber R; Slot S; Zweegman S; Te Boekhorst PA; Senyak Z; Schouten HC; Sackmann F; Fuentes AK; Hernández-Maraver D; Pahl HL; Griesshammer M; Stegelmann F; Döhner K; Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Harrison CN; Radia D; Muxi P; Maldonado N; Besses C; Cervantes F; Johansson PL; Barbui T; Barosi G; Vannucchi AM; Paoli C; Passamonti F; Andreasson B; Ferrari ML; Rambaldi A; Samuelsson J; Cannon K; Birgegard G; Xiao Z; Xu Z; Zhang Y; Sun X; Xu J; Kiladjian JJ; Zhang P; Gale RP; Mesa RA
Haematologica; 2017 Jan; 102(1):85-93. PubMed ID: 27540137
[TBL] [Abstract][Full Text] [Related]
11. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls.
Anderson LA; James G; Duncombe AS; Mesa R; Scherber R; Dueck AC; de Vocht F; Clarke M; McMullin MF
Am J Hematol; 2015 Oct; 90(10):864-70. PubMed ID: 26113113
[TBL] [Abstract][Full Text] [Related]
12. Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition.
Padrnos L; Scherber R; Geyer H; Langlais BT; Dueck AC; Kosiorek HE; Senyak Z; Clark M; Boxer M; Cotter M; Harrison C; Stonnington C; Geda Y; Mesa R
Cancer Med; 2020 Nov; 9(22):8301-8309. PubMed ID: 32976697
[TBL] [Abstract][Full Text] [Related]
13. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.
Scherber R; Dueck AC; Johansson P; Barbui T; Barosi G; Vannucchi AM; Passamonti F; Andreasson B; Ferarri ML; Rambaldi A; Samuelsson J; Birgegard G; Tefferi A; Harrison CN; Radia D; Mesa RA
Blood; 2011 Jul; 118(2):401-8. PubMed ID: 21536863
[TBL] [Abstract][Full Text] [Related]
14. EVALUATION OF BURDENSOME SYMPTOMS IN PATIENTS WITH RADIATION6ASSOCIATED AND SPONTANEOUS MYELOPROILIFERATIVE NEOPLASMS WITH THE USE OF OPTIMIZED SELF-ASSESSMENT MPN-SAF TSS.
Shumeiko OO; Poluben LO; Klimuk BT; Rybchenko LA; Neumerzhitskaya LV; Verbilenko RM; Frolov SV; Klymenko SV
Probl Radiac Med Radiobiol; 2018 Dec; 23():510-516. PubMed ID: 30582868
[TBL] [Abstract][Full Text] [Related]
15. Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
Langlais BT; Mazza GL; Kosiorek HE; Palmer J; Mesa R; Dueck AC
J Hematol; 2021 Oct; 10(5):207-211. PubMed ID: 34804309
[TBL] [Abstract][Full Text] [Related]
16. The SIMM study: Survey of integrative medicine in myeloproliferative neoplasms.
Gowin K; Langlais BT; Kosiorek HE; Dueck A; Millstine D; Huberty J; Eckert R; Mesa RA
Cancer Med; 2020 Dec; 9(24):9445-9453. PubMed ID: 33140580
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and symptom burden of Thai myeloproliferative neoplasm patients.
Cherdchoo N; Polprasert C; Rojnuckarin P; Kongkiatkamon S
Hematology; 2023 Dec; 28(1):2280731. PubMed ID: 37942783
[No Abstract] [Full Text] [Related]
18. Physical Activity as a Nonpharmacological Symptom Management Approach in Myeloproliferative Neoplasms: Recommendations for Future Research.
Eckert R; Huberty J; Gowin K; Mesa R; Marks L
Integr Cancer Ther; 2017 Dec; 16(4):439-450. PubMed ID: 27458250
[TBL] [Abstract][Full Text] [Related]
19. Myeloproliferative neoplasms (MPNs) - Part 2: A nursing guide to managing the symptom burden of MPNs.
Fowlkes S; Murray C; Fulford A; De Gelder T; Siddiq N
Can Oncol Nurs J; 2018; 28(4):276-281. PubMed ID: 31148831
[TBL] [Abstract][Full Text] [Related]
20. Translation, Cultural Adaptation, and Validation into Romanian of the Myeloproliferative Neoplasm Symptom Assessment Form-Total Symptom Score (MPN-SAF TSS or MPN-10) Questionnaire.
Găman MA; Scherber RM; Ursuleac I; Crişan AM; Bădeliţă SN; Ionescu BO; Ghiaur AE; Brînză M; Pîrciulescu N; Lascăr TO; Diaconu CC; Găman AM; Coriu D
J Clin Med; 2024 Jun; 13(11):. PubMed ID: 38892995
[No Abstract] [Full Text] [Related]
[Next] [New Search]